The website is a joint effort between Merck and The Lancet.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.
What will become of Dollars for Docs after the Sunshine provisions go into effect? We asked Charles Ornstein, who told us what's next for the project.
New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.
A new video-based educational series will aim to tailor content to both patients and physicians, the firms behind the effort say.
The drug industry dialed back its continuing medical education (CME) grant-giving in 2011, continuing a negative trend of the last few years.
The Alliance for Continuing Education in the Health Professions (ACEHP) named a new executive director, and mobile health app firm Preventice hired a director of global business development.
The FDA's opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency's scheme educate enough physicians to curb an epidemic?
Damon Marquis wants to make one thing clear: CME is not the only important form of medical education.
Pri-Med founder John Mooney and his former management team have returned to the firm, which is under new ownership following M|C Holding's sale of Pri-Med's US assets to Canadian event and media producer Diversified Business Communications.
The ACCME awarded provisional two-year accreditation to Lighthouse Learning, the educational content provider which develops and sells CME curricula without accepting commercial funding.
In a sign of industry's ongoing desire to broaden its CME funding outlook, a couple of recently supported educational programs by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.
Eli Lilly reported paying $48.1 million to 45,440 physicians and/or 1,827 healthcare organizations during the first quarter, most of it for research and educational programs.
The Florida Department of Health is seeking to sanction a doctor who committed suicide in February, distraught over getting swept up in an off-label promotion sting.
The American College of Cardiology (ACC) is eliminating its traditional model for CME-certified satellite symposia at the Annual Scientific Session.
The American Board of Medical Specialties (ABMS) issued a white paper examining how CME can support its Maintenance of Certification (MOC) requirement in the future. The paper raised hackles among some who saw it as a call for new credit systems.
Lighthouse Learning, which develops and sells CME curricula without taking commercial support, hired Sherri Foster as CME director.
Industry support for continuing medical education (CME) has been waning the last two years, but some say the bottom may be in sight.
A new medical education company has opened offering to produce CME that is free of commercial support.
While the number of physicians open to pharmaceutical sales calls is shrinking, a new survey suggests some venues are more hospitable to industry than others.
Pharma's support for continuing medical education has been narrowing, due to budget cuts and intense scrutiny on commercial funding. However, so-called branded med ed programs have remained a mainstay.
The number of providers placed on probation by the nonprofit that regulates continuing medical education has more than doubled this year, from 15 to 35.
A policy barring pharmaceutical industry employees from giving continuing medical education talks at meetings has elicited strong opposition from physician leaders.
In the last 12 months, 142 medical-education providers either lost their accreditation to offer CME or decided not to apply for renewal, said the ACCME in a report issued last Friday.
Certified and accredited CME has undergone a sea-change in recent years, with policies now in place emphasizing quality and leaving little room for bias (not that you'd know it, for all the buzz about conflicts of interest)
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.